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The tumor suppressor kinase, LKB1 (encoded by STK11), plays important functions in regulating 
diverse cell processes, including cell growth, metabolism, and polarity. As a bioenergetic sensor, 
LKB1 is required for metabolic balancing and maintenance of stem cell homeostasis in the 
haematopoietic system (Gurumurthy et al. 2010; Gan et al. 2010; Nakada, Saunders, and Morrison 
2010) and in muscle (Shan et al. 2014). Intestinal stem cells (ISCs) are regulated by various cues 
from their niche-derived paracrine signals such as NOTCH and WNT (Clevers and Batlle 2013),
and metabolic status (Rodríguez-Colman et al. 2017; Schell et al. 2017). Study I of this thesis 
aimed to investigate whether the metabolic regulator, LKB1, has a role in actively cycling ISCs, 
and identified it as a critical factor for maintaining ISC homeostasis. Mechanistically, LKB1
represses the transcription of the secretory lineage gatekeeper, Atoh1, via pyruvate dehydrogenase 
kinase 4 (PDK4) in ISCs and restricts ISC differentiation towards secretory cell lineages. These 
findings define LKB1 as an essential regulator of ISCs, and provide a connection between 
metabolism and fate determination of ISCs.
Germline mutations inactivating LKB1 lead to gastrointestinal tumorigenesis in Peutz-Jeghers 
Syndrome (PJS) patients (Ylikorkala et al. 1999) and mouse models (Rossi et al. 2002; Bardeesy 
et al. 2002). However, little is known about the cell types and signaling pathways that underlie 
tumor formation, not much has been learnt about the progression of PJS polyposis neither. The 
upregulation of Cyclooxygenase-2 (COX-2) is a feature of PJS polyposis (Rossi et al. 2002; H. 
Takeda et al. 2004), and COX-2 inhibition reduces polyp growth in Lkb1+/− mice modelling PJS 
polyposis (Udd et al. 2004). Study II of this thesis evaluated the effect of the mutagenic 
carcinogen, N-methylnitrosourea (MNU), on gastrointestinal tumorigenesis in Lkb1+/− mice and 
concluded that MNU aggravates Peutz-Jeghers polyposis independently of COX-2. Study III of
this thesis demonstrated that the loss of Lkb1 in mesenchymal progenitor or stromal fibroblasts
leads to the clonal expansion of stromal cells and to the induction of an inflammatory program 
involving the IL-11–JAK/STAT3 pathway, which is critical for tumorigenesis. The findings from 
Studies II and III provide further understanding of the function of LKB1 in Peutz-Jeghers 
tumorigenesis, and suggest potential therapeutic avenues for related tumor diseases.
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LITERATURE REVIEW 
Intestinal Stem Cells (ISCs) 
1. Organization of the intestine 
The embryonic endoderm is one of the three primary germ layers derived during gastrulation, and 
goes on to form the intestinal epithelium. The endoderm generates the embryonic gut tube by 
extensive folding under induction and molecular patterning (Noah, Donahue, and Shroyer 2011).
The gut tube gradually divides into three parts, including the foregut, midgut, and hindgut, with
the midgut giving rise to the colon and small intestine. Longitudinally (along the rostral-caudal 
axis), the small intestine can be subdivided into three anatomical segments: the duodenum, the 
jejunum, and the ileum (Vooijs, Liu, and Kopan 2011; van der Flier and Clevers 2009).
There are four layers in the composition of intestinal tract in all the anatomical segments: the 
outermost layer of loose connective tissue –termed adventia layer (or serosa)– contains blood 
vessels, lymphatics and nerves, covered by the visceral peritoneum. The next is smooth muscle 
layer –termed muscularis propria– composted by a circular muscle layer (inner) and a longitudinal 
muscle layer (out), executes the peristaltic movements to deliver food down through the gut. 
Below the muscularis propria there comes the third layer –termed submucosa– a loose connective 
tissue layer consists larger blood vessels, lymphatics, nerves, and mucous secreting glands. The 
innermost layer termed mucosa, is made up of three layers –an inner mucous epithelium that is 
composed of a single layer of lining epithelial cells, the lamina propria that consists loose fibrous 
connective tissue that provides vascular support for the epithelium, and a thin double layer of 
smooth muscle called the muscularis mucosa for local movement of the mucosa. The mucosa 
functions essentially for food digestion, nutrients absorption and pathogen defense (Treuting, 
Valasek, and Dintzis 2012). The absorptive surface of the small intestine is dramatically increased 
by numerous luminal protrusions, termed villi, and invaginations into the submucosa, the crypts 
(Sancho, Batlle, and Clevers 2004).
A cross section at microscopic or histologic view of the intestinal epithelium (Scheme shown in 
Figure 1, left) displays how crypts and villi are organized with various epithelial lineages. The 
crypts invaginate into the underlying submucosa as a pit in which the ISCs reside at the bottom.
These pits also consist of Paneth cells and transit-amplifying progenitors. The villi are finger-like 
protrusions that project into the lumen to increase the surface area of the intestinal wall for nutrient 
absorption. Each villus is surrounded by six or more crypts, which continually produce all types 
of epithelial cells from ISCs to replenish the rapidly renewing intestinal epithelia (van der Flier 
and Clevers 2009).
2. Intestinal epithelial cell lineages  
The intestinal epithelium is the fastest self-renewing tissue in mammals, with a turnover rate of
4–5 days. To replenish the rapidly renewing epithelium, there are new cells constantly generated 
by the intestinal stem cells (LGR5+ ISCs) residing at the bottom of the crypts (Barker et al. 2007; 
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van der Flier and Clevers 2009; Watt and Hogan 2000; Clevers 2013). The stem cells divide 
symmetrically every day and give rise to two equipotential daughter cells, which stochastically 
adopt either a stem or bipotent progenitor cell fate following the neutral drift of niche factors 
(Snippert et al. 2010). The bipotent progenitors (Bi-Pro) are the immediate progeny of ISCs in the 
TA (transit-amplifying) zone (Kim et al. 2016), and they quickly adopt either a secretory 
progenitor (Sec-Pro) or an absorptive progenitor (enterocyte progenitor, Ent-Pro) fate via lateral 
inhibition. The TA progenitor pool spends 2–3 days in the crypt and divides approximately every 
12–18 hours, or a total of 4–6 times prior to fully differentiating into the various epithelial lineages. 
This process gives rise to approximately 300 cells per day (Carulli, Samuelson, and Schnell 2014; 
Marshman, Booth, and Potten 2002) (Figure 1, right).  
The progenitors, while dividing, become committed to specific lineages and cell types, finally 
leading to mitotically inactive, fully mature secretory or absorptive cells as they migrate out of 
the crypt. The secretory cells include mucous-secreting goblet cells, peptide hormone-secreting 
enteroendocrine cells, Paneth cells, and tuft cells, while the absorptive cells are enterocytes, that 
take up the majority of the epithelium (Figure 1, right) (Carulli, Samuelson, and Schnell 2014; 
van der Flier and Clevers 2009; Sato et al. 2011). Unlike the other terminally differentiated cells, 
Paneth cells reside at the bottom of the crypt for 6-8 weeks, providing essential signals for stem 
cell maintenance (Sato et al. 2011). 
 
 
Figure 1. Organization of the intestinal epithelium. The intestinal crypt consists of intestinal stem 
cells, Paneth cells, and Transit-amplifying Progenitors (TA progenitors). The intestinal villi consist 
of terminally differentiated enterocytes, goblet cells, enteroendocrine cells, tuft cells. The LGR5+ 
ISCs keep self-renewing and give rise to the Bipotent-Progenitors (Bi-Pro), which then decide to 
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become either Secretory-Progenitors (Sec-Pro) or Enterocyte-Progenitors (Ent-Pro) depending on the 
signals received. Although Wnt signals promote secretory differentiation and absorptive 
differentiation is induced by active Notch, there is interplay between the two signaling pathways to
regulate the intestinal epithelial differentiation. The Bi-Pro will take the route to become Sec-Pro 
when the secretory lineage gatekeeper, ATOH1, gets induced. They further differentiate to various 
mature secretory cell types depending on the regulation of secretory lineage genes that are 
downstream of ATOH1. The enterocytes are generated by the Ent-Pro. (Gerbe et al. 2011)
3. LGR5+ intestinal stem cells 
The definition of stem cells may vary with the concepts of research interests and the system under 
analysis. The intestinal epithelium, that holds the most rapid renewing rate among the adult steady-
state renewing tissues, a definition was formulated by Potten & Loeffler in 1990 and described 
with following terms: relatively undifferentiated, proliferative cells that maintain their numbers 
(self-renew), while at the same time producing a range of differentiated progeny that may continue 
to divide (potentiality of generating multiple lineages) (C.S. Potten and Loeffler 1990).
Prior to the genetic identification of stem cells with specific markers, there was a debate over the 
location and identity of ISCs. Based on an early DNA-label-retention study, the cycling “+4 cells”,
that locate at approximately four cell positions immediately above the base of the crypt, were 
proposed as the ISCs (Christopher S. Potten, Booth, and Pritchard 1997), and this has been widely 
recognized for a long time thereafter. An alternative view proposed the crypt base columnar (CBC) 
cells, that locate at the base of the crypt intermingled with the Paneth cells, as the true ISCs (Carulli, 
Samuelson, and Schnell 2014).
The first genetic identification of ISCs was described in the landmark paper published in 2007 by
Nick Barker and Hans Clevers (Barker et al. 2007). Lgr5, a G-protein coupled receptor and a
facultative component of the Wnt receptor complex that acts as a receptor for R-spondin1 (RSPO1)
(De Lau et al. 2011), was found to be a specific marker of CBC cells (Barker et al. 2007). By 
generating Lgr5EGFP-IRES-creERT2/+ mice,  the Clevers group functionally demonstrated that LGR5+
cells are stem cells which are capable of producing all of the mature cell types in the intestinal
epithelium (Barker et al. 2007). This conclusion was achieved through a lineage tracing strategy
(with a Rosa26R-LacZ reporter in their setting) , using a technique that allows permanent 
activation of a reporter gene in a cell and all of its progeny and is therefore considered as the gold 
standard for defining a stem cell in vivo (Bjerknes and Cheng 2002). In addition, isolated LGR5+
cells were subsequently shown to possess the capacity to produce intestine-like tissue grown in 
perpetuity in vitro, termed intestinal organoids (enteroids), providing another line of evidence of
stem-like function (Sato et al. 2009).
Despite the fact that the LGR5+ CBC cells had been established as the cycling stem cells, there 
are many additional studies supporting the idea of another stem cell population that resides in the 
approximately +4 position. Studies utilizing immunostaining and lineage tracing identified a 
number of putative markers of this population including Bmi1 (Sangiorgi and Capecchi 2008),
Hpox (N. Takeda et al. 2011), Lrig1 (Powell et al. 2012; Wong et al. 2012), and mTert (Breault et 
al. 2008; Montgomery et al. 2011). Similar to the Lgr5 study, the +4 lineage tracing experiments 
demonstrated that the +4 cells are a quiescent, or reserve stem cell (QSC) population that divides 
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more slowly but can be activated to both produce all of the differentiated intestinal cell types, in 
response to depletion of LGR5+ cells and drive regeneration after injury (Breault et al. 2008; 
Powell et al. 2012; Montgomery et al. 2011; Yan et al. 2012; N. Takeda et al. 2011; Tian et al. 
2011).
Although there is abundant lineage tracing data supporting the idea of those +4 genes that mark
the QSCs, whether these cells are truly an independent stem cell population still remains as a 
debate. The argument mostly arises from studies that find those QSC markers also express in 
cycling stem cells (Table 1) (Muñoz et al. 2012; Itzkovitz et al. 2012; Carulli, Samuelson, and 
Schnell 2014).
Table 1. Intestinal stem cell markers
Gene Expressed in Reference
Lgr5 CBC cells and +4 cells (low) (Barker et al. 2007)
Ascl2 CBC cells (van der Flier, van Gijn, et al. 2009)
Smoc2 CBC cells (Muñoz et al. 2012)
Olfm4 CBC cells (van der Flier, Haegebarth, et al. 2009)
Rnf43 CBC cells (Koo et al. 2012)
Znrf3 CBC cells (Koo et al. 2012)
Troy (Tnfrsf19) CBC cells (Fafilek et al. 2013)
Prom1 CBC cells and +4 cells (Snippert et al. 2009)
Sox9 CBC cells and +4 cells (Gracz, Ramalingam, and Magness 2010; Van 
Landeghem et al. 2012; Roche et al. 2015)
Msi1 CBC cells and +4 cells (Christopher S. Potten et al. 2003)
Lrig1 CBC cells and +4 cells (Powell et al. 2012; Wong et al. 2012; Muñoz et 
al. 2012)
Bmi1 CBC cells and +4 cells (Sangiorgi and Capecchi 2008; Tian et al. 2011; 
Itzkovitz et al. 2012; Muñoz et al. 2012)
mTert CBC cells and +4 cells (Breault et al. 2008; Montgomery et al. 2011; 
Itzkovitz et al. 2012; Muñoz et al. 2012)
Hopx CBC cells and +4 cells (N. Takeda et al. 2011; Muñoz et al. 2012)
Location-wise, Paneth cells are in close association with the LGR5+ ISCs, with over 80% of the 
LGR5+ ISC surface area in contact with neighboring Paneth cells (Sato et al. 2011). Unlike other 
terminally differentiated cell types that migrate up the villi and shed off from the tip into the lumen 
with a life span of about 3–5 days, Paneth cells migrate down towards the crypt base, where they 
persist for approximately 6-8 weeks (Sato et al. 2011). Paneth cells express signaling molecules 
such as WNT3, EGF, TGFα, and DLL4, which are essential for the maintenance of ISCs. Together 
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with the important finding from the Clevers group that co-culturing the isolated LGR5+ ISCs 
together with CD24+ Paneth cells dramatically improves the organoid formation capacity of the 
ISCs (Sato et al. 2011), the Paneth cells are believed to serve as niche for LGR5+ ISCs.
4. Regulation of stemness and differentiation  
The LGR5+ ISCs have the capacity of both self-renewal and multipotency—the properties that 
define stem cells. How ISCs make the decision to self-renew or differentiate is incompletely
understood. In the current view, there are four major signaling pathways coordinatively regulating 
this process at the crypt base in a cell-extrinsic manner, meaning that the growth factors that are 
present are secreted by neighboring Paneth cells or the surrounding mesenchyme: Wnt, Notch, 
Bmp and Egf (Clevers and Batlle 2013). The most well-studied pathways that are critical to the 
development and maintenance of the intestinal epithelium are the Wnt and Notch pathways.
Wnt signaling is required for ISC and progenitor cell proliferation and is also implicated in 
regulating aspects of cell differentiation, likely through cross-talk with the Notch signaling 
pathway (Crosnier, Stamataki, and Lewis 2006). Genetic ablation of Wnt signaling disrupts 
normal homeostasis and leads to loss of the crypts (Fevr et al. 2007). Wnt signaling is activated 
by Wnt ligands, which are secreted from Paneth cells (Kim and Shivdasani 2011) or alternatively 
from the mesenchymal compartment (Farin, Van Es, and Clevers 2012), and bind to the Frizzled
(FZD) receptor on Wnt-responding ISCs. The E3 ubiquitin ligases, RNF43/ZNRF3, suppress Wnt 
signaling by targeting FZD receptors for lysosomal degradation (Koo et al. 2012). Lgr5 and its 
homologs, Lgr4 and Lgr6, constitute the receptors for R-spondins (RSPO), and the Lgr5/RSPO 
complex reinforces Wnt signaling by neutralizing RNF43/ZNRF3 E3 ligases (De Lau et al. 2011; 
de Lau et al. 2014). Activated Wnt stabilizes β-catenin through a cascade of events and leads to
the accumulation and nuclear translocation of β-catenin, which forms a complex with TCF/LEF
and other co-activators (Martin-Orozco et al. 2019). This enhances transcriptional activation of
TCF/LEF target genes such as Lgr5 and c-Myc to maintain stemness and drive proliferation (Sato 
and Clevers 2013).
The Notch signaling pathway is also essential in controlling lineage specification in the intestinal 
epithelium. Active Notch signaling in proliferative stem and progenitor cells leads to 
differentiation towards absorptive lineages while blocked Notch signaling results in secretory 
lineage differentiation (Van Es et al. 2005). The Notch ligands, DLL1+DLL4+, secreted from
Paneth cells trigger signaling in neighboring ISCs with Notch receptors NOTCH1/2, thus keeping 
them from secretory differentiation (Pellegrinet et al. 2011). The activated Notch signaling in ISCs 
leads to γ–secretase-mediated proteolytic release of the Notch intracellular domain (NICD) to the 
nucleus. NICD binds to the transcription factor recombination signal-binding protein J kappa 
(Rbpj, also known as CBF-1 or CSL) to activate transcription of the Notch target gene, Hes1,
which represses Atoh1 expression and promotes an absorptive rather than secretory cell fate
(Jensen et al. 2000; Clevers 2013). Thus, the absorptive/secretory cell fate switch of ISCs and 
their immediate progeny (bi-potential progenitors) (Kim et al. 2016) following their exit from the 
crypt base due to neutral competition (Snippert et al. 2010) seems to be controlled through Notch 
by lateral inhibition (Artavanis-Tsakonas, Rand, and Lake 1999).
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5. ATOH1, an intestinal secretory cell gatekeeper 
Atonal bHLH Transcription Factor 1 (ATOH1, also known as MATH1) belongs to the basic helix-
loop-helix (bHLH) family of transcription factors and is required for all secretory cell lineage 
differentiation (Q. Yang et al. 2001; Shroyer et al. 2007). ATOH1 reinforces its own expression 
and directly regulates Dll1 and Dll4 to control lateral inhibition, thus enabling Notch-dependent 
Atoh1 repression in neighboring cells (Kim et al. 2014). Furthermore, it induces a number of its 
downstream secretory lineage genes: Growth factor independent 1 transcriptional repressor (GFI1)
for goblet and Paneth cell differentiation (Shroyer et al. 2007) and Neurogenin-3 (NEUROG3) for 
enteroendocrine cell differentiation (Jenny et al. 2002).
In ISCs, ATOH1 is repressed at a low level (by Paneth cells) and in enterocytes as well via lateral 
inhibition by the canonical Delta-Notch-RBPjk-Hes1 signaling cascade (Jan and Jan 1994).
Genetic ablation of the Notch effector, RBP-J (Van Es et al. 2005; Kim and Shivdasani 2011), or 
pharmacological inhibition using γ-secretase inhibitor (GSI) Dibenzazepine (DBZ) (Milano et al. 
2004; Van Es et al. 2005; van Es et al. 2010) both lead to Notch inhibition and result in the loss 
of ISCs (van Es et al. 2010) and an increase in all intestinal secretory lineages in the crypts (Kim 
and Shivdasani 2011; Van Es et al. 2005; van Es et al. 2010), and this is mediated by induced 
Atoh1 expression (Kim and Shivdasani 2011; van Es et al. 2010). Consistently, transgenic 
expression of Atoh1 in the epithelium resembles Notch inhibition and converts ISCs and 
progenitors to secretory cells both in vivo (VanDussen and Samuelson 2010) and ex vivo (Koo et 
al. 2012). There is an interplay between Notch and Wnt signaling, or, more precisely, Notch 
activity is required for maintaining the correct balance of Wnt signaling in the crypts, which 
regulates Atoh1 expression in a cell-extrinsic manner and allows for simultaneous maintenance of 
ISCs, proliferation, and differentiation (Tian et al. 2015).
6. Metabolism in stem cell fate determination 
While the self-renewal and differentiation of ISCs is largely controlled by coordinated regulation 
of well-characterized Notch and Wnt signaling pathways, emerging evidence highlights the 
contribution of energy metabolism to the regulation of ISC function (Rodríguez-Colman et al. 
2017; Schell et al. 2017; Beyaz et al. 2016). In Rodríguez-Colman et al., the authors examined the 
metabolic identity of LGR5+ CBCs and Paneth cells in supporting optimal stem cell function, and 
identify mitochondria and reactive oxygen species signaling as driving cellular differentiation
(Rodríguez-Colman et al. 2017). In Schell et al., it was reported that intestinal stem cell function 
and proliferation can be controlled by mitochondrial pyruvate metabolism (Schell et al. 2017).
Another observation described in Beyaz et al. demonstrated that high-fat diet (HFD)-induced 
obesity enhances stemness, as evidenced by augmented numbers and function of LGR5+ intestinal 
stem cells of the mammalian intestine (Beyaz et al. 2016).
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The LKB1 kinase  
1. LKB1 as a kinase 
The STK11 gene encodes Liver Kinase B1 (LKB1), a widely expressed serine/threonine kinase
and it was also established as a gene that can cause sporadic tumorigenesis due to somatic impaired 
encoded protein kinase activity (Ylikorkala et al. 1999)
LKB1 phosphorylates and activates its fourteen downstream intracellular kinases, including the 
well-known AMP-activated protein kinase α1 (AMPKα1) and AMPKα2, NUAK1/2, SIK1–3,
SNRK, BRSK1/2, and MARK1–4. Through activation of these kinases, LKB1 regulates multiple 
signaling pathways functioning in essential cell processes, including protein synthesis, cell 
proliferation, metabolism, and polarity (Katajisto et al. 2007).
Full kinase activity can be reached only when LKB1 forms a trimeric complex with two other 
proteins, the pseudokinase STRAD and the scaffolding protein MO25, which also stabilize the 
LKB1 protein and anchor it in the cytoplasm, where it can mediate its known cellular functions 
through phosphorylating the downstream substrates (Baas A et al. 2003; Boudeau J et al. 2003).
2. LKB1 as a metabolic regulator
AMP-activated protein kinase (AMPK) was the first identified and best characterized substrate 
for the LKB1 kinase (Hawley et al. 2003; Woods et al. 2003; Shaw, Kosmatka, et al. 2004). When 
there is a lowered energy potential inside the cell, reflected in high AMP/ATP ration, the 
activating allosteric changes induced by AMP allows the Thr172 in AMPK to be phosphorylated 
by upstream kinase LKB1 (Xiao et al. 2013). For AMPK to be active, the heterotrimeric AMPK 
complex consisting of an α catalytic subunit (AMPKα) and two regulatory subunits (AMPKß and 
AMPKγ), needs to bind AMP in order to allow the activating phosphorylation by LKB1 (Hawley 
et al. 2003).
AMPK activation leads to a switch from energy consumption to energy generation, represented 
as a restoration of energy balance by catabolic-process promotion and anabolic-process inhibition. 
The reprograming of cellular metabolism by AMPK is conducted through the phosphorylation of 
its downstream substrates with cascade events. The promoted catabolic processes include, for 
instance, fatty acid uptake, glucose uptake, glycolysis, and autophagy. And the inhibition of 
energy consuming anabolic processes mainly include fatty acid synthesis suppression via acetyl-
CoA carboxylase (ACC), as well as the downregulation of mTORC1-dependent translation, cell 
growth and proliferation (Hardie and Alessi 2013; Shorning and Clarke 2016; Garcia and Shaw 
2017). Therefore AMPK functions as the cellular energy sensor, and LKB1, as the upstream 
kinase of AMPK, plays important role as a metabolic regulator.
3. Lkb1 in adult stem cells 
Although recent study reported that ISCs exhibit high mitochondrial activity and oxidative 
phosphorylation (Rodríguez-Colman et al. 2017), however, in contrast to the ISCs, many other 
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adult stem cells including the haematopoietic stem cells (HSCs) and mesenchymal stem cells 
(MSCs) reside in a hypoxic niche and reliant on anaerobic glycolysis (Ito and Suda 2014).
Lkb1 is critical for the maintenance of stem cell homeostasis in the haematopoietic system (for 
HSCs) (Gurumurthy et al. 2010; Gan et al. 2010; Nakada, Saunders, and Morrison 2010) and in
muscle (Shan et al. 2014). In both cases, Lkb1 loss disrupts stem cell quiescence and lifts an initial 
temporary cell proliferation; but eventually, the former ends up with a depletion of HSCs, and the 
latter undergoes a defective differentiation of muscle progenitors. And the reason for both cases 
is mitochondrial defects and altered energy metabolism due to the loss of Lkb1.
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LKB1 in Peutz-Jeghers Syndrome 
Peutz-Jeghers syndrome (PJS) is a rare hereditary autosomal dominant cancer predisposition 
disease (Eng, Hampel, and Chapelle 2001), characterized by dark blue or dark brown 
mucocutaneous pigmentation as an early sign and multiple benign hamartomatous polyps 
developed in gastrointestinal (GI) tract as the main symptoms, as well as increased risk of various 
types of malignant cancer (Van Lier et al. 2011). The cause of PJS is germline mutations that 
inactivate STK11 encoding the LKB1 tumor suppressor kinase (Aretz et al. 2005; Hemminki et al. 
1998).
About half of the PJS patients display small intestinal obstruction or intussusception at their early 
age due to benign gastrointestinal polyps, which have to treated with repeated surgical removal 
(Utsunomiya et al. 1975). Besides the small intestine (64%) where polyps most commonly occur, 
there is also involvement with the colon (53%), stomach (49%), and rectum (32%), and rare cases 
have also been found in the upper and lower respiratory tract and bladder. The presenting 
symptoms in PJS patients include abdominal pain, rectal bleeding, anemia, small intestinal 
intussusception, bowel obstruction, and rectal prolapse of polyps. PJS is associated with increased 
risk of malignancy, and the mortality in PJS patients is mainly due to various malignancies rather 
than polyposis (Zbuk and Eng 2007; Shorning and Clarke 2016). A follow-up study restricted to 
PJS patients with LKB1 germline mutations demonstrated that about 81% of these patients
developed any type of cancer by the age of 70. And the most commonly observed cancer is 
colorectal, followed by breast, small bowel, gastric and pancreatic malignancies (Lim et al. 2004).
The PJS polyps have no defining features on endoscopy, however, they display extensive stromal 
compartment with an elongated arborizing smooth muscle core microscopically. And this 
prominent smooth muscle core serves as the defining attribute of a PJS polyp (Estrada and Spjut 
1983). Haploid loss of LKB1 is sufficient for polyp formation in Lkb1+/- mice, which develop 
gastrointestinal polyps that are histologically indistinguishable from PJS polyps, therefore Lkb1+/-
mice are used to model the PJS polyposis (Rossi et al. 2002) (Table 2). Mice with haploid loss of 
LKB1 that is restricted to stromal smooth muscle cells also develop polyps, however, with lower 
penetrance and smaller size compared to Lkb1+/- mice in which both the GI stroma and epithelium 
are heterozygous for Lkb1 loss (Katajisto et al. 2008).
The upregulated expression of COX-2, an enzyme eminently attribute to control the inflammatory 
reaction, has been determined as a feature of the hamartomatous polyposis in both PJS patients 
and Lkb1+/- mice (Rossi et al. 2002; de Leng et al. 2003). Knockout of Cox-2, or inhibition of 
COX-2 with celecoxib, can partially suppress PJS polyposis by reducing the size but not the 
number of tumors (Udd et al. 2004).
Recent studies have identified increased inflammatory signaling upon Lkb1 loss in different cell 
and tissue contexts, such as in T cells (MacIver et al. 2011), macrophages (Liu et al. 2015), skeletal 
muscle (Chen et al. 2016), and lung cancer (Koyama et al. 2016), indicating Lkb1 as a suppressor 
of inflammatory pathways. Taking into account the role of COX-2 in PJS polyposis, it would be 
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highly interesting to investigate the potential role of inflammatory pathways in PJS pathogenesis,
which currently remains unknown.
Decrease or disappearance of the pepsinogen expression in pyloric mucosa has been regarded as 
a marker of preneoplasia in the stomach in rat, during the early stages of N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG)-induced gastric carcinogenesis before distinct morphological lesions 
arise (Furihata et al. 1975). Decreased pepsinogen expression is also observed in adenomas and 
carcinomas (Tatematsu et al. 1987). Such alteration of pepsinogen expression (pepsinogen-altered 
pyloric glands, PAPG) can be detected immunohistochemically in normal-looking pyloric mucosa. 
The mutagenic carcinogen N-Methylnitrosourea (MNU), a DNA-alkylating agent, can induce 
gastric carcinogenesis in several mouse strains, where PAPG have been found to be induced dose-
dependently by MNU-treatment, and correlate with a higher proliferative activity than the normal 
counterpart epithelium (Yamamoto et al. 1997, 2002). Therefore, PAPG may be a precursor 
generally representing the preneoplastic lesion for gastric chemical carcinogenesis in rodents. In 
Lkb1+/- mice, stomach glands display aberrant or incomplete differentiation as detected by 
pepsinogen C staining, which shows an increased frequency of PAPG (Udd et al. 2010).
Table 2. Lkb1 knockout mouse models discussed in this thesis
* heterozygous (het), homozygous (hmz)
Genotype Tissue involved Phenotype (with Reference)
Lkb1+/- all tissues het PJS GI polyposis (Bardeesy et al. 2002; Jishage et al. 2002; Miyoshi 
et al. 2002), polyp COX-2 upregulated (Rossi et al. 2002; H. Takeda 
et al. 2004), Wnt-signaling deregulated (Lai et al. 2011), polyp mTOR 
signaling upregulated (Shaw, Bardeesy, et al. 2004), Osteoblastosis 
and benign osteogenic tumors (Robinson et al. 2008), well-
differentiated endometrial adenocarcinomas in 50% of females 
(Contreras et al. 2008), Hepatocellular carcinomas in 70% of males




smooth muscle cells 
het





smooth muscle cells 
hmz
PJS GI polyposis, stronger tumorigenicity than Lkb1fl/+;TagInSM-
CreERT2 + i.p. TAM mice (Katajisto et al. 2008).
Lkb1fl/fl;Ah-Cre 
+ i.p. ß-NF
many tissues hmz, 
at least prostate, 
liver, GI epithelium, 
others hypomorph 
Altered differentiation in GI epithelium with the appearance of 
intermediate cells and increase in angiotensin related signaling 
molecules, especially Ang II and renin, also defective Par-1 signaling 




effect, in most 
tissues
Pancytopenia in 24-35 days, bonemarrow failure, lethality within 120 
days due to pancytopenia, an initial and temporary proliferation 
increase in HSCs, but a rapid depletion thereafter (Gurumurthy et al. 










all tissues Severe pancytopenia within 1 week, lethality within 30 days, first days 
after ablation HSC proliferate, then die through apoptosis, WT mice 
reconstituted with Lkb1 KO bonemarrow die within 60 days (Gan et 




Premature death, due to severe myopathy characterized by central 





also known as 
satellite cells or 
muscle stem cells
Lkb1 null satellite cells lose their regenerative capacity cell-
autonomously, fail to maintain quiescence in noninjured resting 
muscles and exhibit accelerated proliferation but reduced 
differentiation kinetics (Shan et al. 2014).
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AIMS OF THE STUDY 
I To investigate the potential role of Lkb1 in intestinal stem cell fate determination 
by using genetically engineered mouse models and their derived three-dimensional 
organoid cultures with stem-cell-specific deletion of Lkb1, as well as LKB1-
depleted human cancer cell lines.
II To evaluate the effect of MNU treatment on gastrointestinal tumorigenesis in 
Lkb1+/- mice modelling Peutz-Jeghers polyposis, and to assess the efficiency of 
COX-2 inhibition in this setting.
III To identify the mechanism by which Lkb1 mutations lead to Peutz-Jeghers 
Syndrome tumorigenesis by using genetically engineered mouse models, organoid 
cultures, and mouse embryonic fibroblast (MEF) cells.
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MATERIALS AND METHODS 
1. Materials 
The materials used in this study are listed below with references. More detailed information can 
be found in the original publications referred to with Roman numerals.
Mouse line
Name Description Source/reference Used in
Lgr5EGFP-IRES-creERT2/+ Heterozygous mice harbor an Lgr5-
EGFP-IRES-creERT2 “knock-in” allele 
that expresses EGFP and CreERT2 fusion 
protein. When bred with mice containing a 
loxP-flanked sequence of interest, Cre-
mediated recombination will result in 
deletion of the floxed sequences in the 
Lgr5-expressing cells of the offspring 
upon the induction with Tamoxifen.
Clevers lab (Barker 
et al., 2007)
I, III
Lkb1flox/flox Homozygous mice harbour conditional 
alleles flanking exons 3-6 of Lkb1 (Stk11). 
When bred with mice containing the Cre 
recombinase-expressing allele, Lkb1 is 
deleted.
DePinho lab 
(Bardeesy et al., 
2002)
I, III
Rosa26LSL-TdTomato/+ Also referred to as Ai14 mice. These mice 
harbor a Cre reporter allele designed to 
have a loxP-flanked STOP cassette 
preventing transcription of a CAG 
promoter-driven red fluorescent protein 
variant (tdTomato) – all inserted into 
the Gt(ROSA)26Sor locus. When bred 
with mice containing the Cre-
recombinase-expressing allele, the 




(Madisen et al., 
2010)
I, III
CD1 Outbred mice derived from a group of 
outbred Swiss mice developed at the Anti-
Cancer Center in Lausanne, Switzerland. 
The CD-1 IGS mice are generally used for 





C57BL/6J Also known as Black 6, B6, B6J, C57 
Black. C57BL/6J mice are the first strain 
to have its genome sequenced, and the 





transgenic and knockout model 
development (the wild-type C57BL/6J
mice are a good control), obesity and 
immunological studies as well. This strain 
is a permissive background for maximal 
expression of most mutations, though it is 
refractory to many tumors.
Lkb1+/- Mice heterozygous for Lkb1 that develop 
hamartomatous polyps that are 
indistinguishable from the human polyps, 
thereby serving as a disease model.
Mäkelä lab
(Ylikorkala et al. 
2001)
I,II, III
Fsp1-Cre Also known as S1004A-Cre. These 
transgenic mice express Cre recombinase 
under the control of the mouse S100a4,
S100 calcium binding protein A4, 
promoter. Cre recombinase expression is 
detected specifically in stromal fibroblasts 
of tissues such as the prostate, forestomach
and mammary gland.
Leone lab





These Twist2-Cre (Dermo1-Cre) mutant 
mice harbor a Cre recombinase knock-in 
allele that also abolishes endogenous twist 
homolog 2 (Twist2) gene function.
Heterozygotes are viable and fertile, while 
homozygotes (Twist2-/-) die a few days 
after birth. Cre recombinase activity is 
reported in the mesoderm as early as 
embryonic day 9.5, as well as in 
mesodermal tissues such as branchial 
arches and somites, and in condensed 
mesenchyme-derived chondrocytes and 
osteoblasts.
The Jackson





The targeted mutant mice carry a loxP-
flanked neo cassette upstream of a β-
galactosidase (lacZ) sequence. Removal of 
the neo cassette by Cre recombination 
results in lacZ expression in Cre-
expressing tissues of the offspring.
The Jackson 
Laboratory 





Also known as mT/mG. Rosa26R-mTmG 
is a cell membrane-targeted, two-color 
fluorescent Cre-reporter allele. Prior to 
Cre recombination, cell membrane-
localized tdTomato (mT) fluorescence 
expression is widespread in cells/tissues. 
Cre-recombinase-expressing cells (and 
future cell lineages derived from these 
cells) have cell-membrane-localized 
The Jackson 
Laboratory 




EGFP (mG) fluorescence expression 
replacing the red fluorescence.
Rosa26R-Confetti 
reporter
Also known as R26R-Brainbow2.1 , 
Rosa26-CAG-Brainbow2.1/Confetti.
Homozygous R26R-Confetti mice are 
viable and fertile. The R26R-Confetti 
conditional allele contains the Brainbow 
2.1 cassette, which has a ubiquitous CAG 
promoter followed by a loxP-flanked 
NeoR-cassette whose polyadenylation 
sequence terminates transcription of the 
downstream 4 fluorescent reporter genes, 
encoding for a nuclear-localized green 
fluorescent protein (hrGFPII), a 
cytoplasmic yellow fluorescent protein 
(mYFP), a cytoplasmic red fluorescent 
protein (tdimer2(12)) and a membrane-
tethered cyan fluorescent protein 
(mCerulean) fluorescent proteins, 
positioned in two tandems. No 
fluorescence is expressed prior to Cre 
activation. Cre-mediated recombination 
simultaneously excises the NeoR-cassette 
and leads to the production of certain 
fluorescent proteins depending on which 








Name Description Source/reference Used in
HEK293FT Human embryonic kidney ATCC I
Ls174t Human colorectal adenocarcinoma ATCC I
Antibodies
Name Description Source/reference Used in
anti-GAPDH Rabbit monoclonal, WB Cell Signaling, #2118 I, III
anti-Vinculin Mouse monoclonal, WB Sigma, V9131 I
anti-LKB1 Mouse monoclonal, WB Abcam, ab15095 I, III
anti-cleaved Notch1 Rabbit monoclonal, WB Cell Signaling, #4147 I
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anti-Phospho-S6 Rabbit polyclonal, WB Cell Signaling, #2211 I
anti-S6 Rabbit monoclonal, WB Cell Signaling, #2217 I
anti-Phospho-Acetyl-CoA 
Carboxylase
Rabbit polyclonal, WB Cell Signaling, #3661 I
anti-Acetyl-CoA 
Carboxylase
Rabbit polyclonal, WB Cell Signaling, #3662 I
anti-PDK4 Mouse monoclonal, WB Abcam, ab110336 I
anti–STAT3-phosphoY705 Rabbit monoclonal, WB Cell Signaling, #9145 III
anti-STAT3 Rabbit polyclonal, WB Cell Signaling, #9132 III
anti-ERK1/2-
phosphoT202/204
Rabbit monoclonal, WB Cell Signaling, #4695 III
anti-ERK1 Rabbit polyclonal, WB Santa Cruz 
Biotechnology, sc-94
III
anti-GFP Goat polyclonal, IF and IHC Abcam, ab5450 I, III
anti-RFP Rabbit polyclonal, IF and 
IHC
Rockland, 600-401-379 I, III
anti-LKB1 Rabbit monoclonal, IHC Cell Signaling, #13031 I
anti-PDK4 Rabbit polyclonal, IHC Abcam, ab71240 I
anti-pepsinogen C Rat, IHC (Furihata et al., 1973) II
anti-p53 Mouse monoclonal, IHC Invitrogen, 13-4100 II
anti-Ki-67 Rat monoclonal, IHC DAKO, M7249 II, III
anti-Fsp1 Rabbit Polyclonal, IHC DAKO, A5114 III
anti-αSMA Mouse monoclonal, IHC Sigma, A2547 III
anti-vimentin Rabbit monoclonal, IHC Abcam, ab92547 III
anti-Ki67 Rabbit polyclonal, IHC Abcam, ab15580 III
anti-CD45 Rabbit polyclonal, IF Abcam, ab10588 III
anti-CD24 Rat monoclonal, Pacific blue 
conjugated, FACS
Biolegend, 101820 I





Growth factors and supplements in organoid culture
Name Description Source/reference Used in
EGF Recombinant full-length mouse EGF 





Noggin Recombinant full-length mouse Noggin 




R-spondin1 Recombinant truncated mouse R-
spondin protein (Ser21-Gly209), for 
organoid culture.




N2 supplement A chemically defined, serum-free 





B27 supplement A serum-free supplement ideal for the 
cultivation of neural progenitor and stem 
cells, either as neurospheres in 
suspension or in adherent monolayer 




IL-6 Recombinant Human IL-6 Protein. R&D, E. coli derived,
206-IL-01
III





Rho-associated protein kinase (ROCK)
inhibitor.
Sigma, Y0503 I, III
N-Acetyl-L-
cysteine (NAC)
NAC has been used as a component of 
intestinal basal medium for the culture of 
mouse intestinal stem cells and also as a 
component of expansion medium.
A9165 I, III
Plasmids
Name Description Source/reference Used in
pLKO.1-puro-
shNT
pLKO.1 lentiviral vector for expression 
non-targeting shRNA, with Puromycin 
antibiotic resistant gene for selection 
stable cell line.
The RNAi Consortium





pLKO.1 lentiviral vector for expression 
shRNA targeting human LKB1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting human LKB1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting human LKB1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting human LKB1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 






pLKO.1 lentiviral vector for expression 
shRNA targeting human PRKAA1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting human PRKAA1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting human PRKAA2, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting human PRKAA2, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting human ATOH1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
non-targeting shRNA, with 
Hygromycin antibiotic resistant gene
for selection stable cell line.





pLKO.1 lentiviral vector for expression 
shRNA targeting human ATOH1, with 
Hygromycin antibiotic resistant gene for
selection stable cell line.





pLKO.1 lentiviral vector for expression 
shRNA targeting mouse Nuak1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting mouse Nuak2, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting mouse Mark1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting mouse Mark2, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting mouse Mark3, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 






pLKO.1 lentiviral vector for expression 
shRNA targeting mouse Mark4, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting mouse Sik1, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting mouse Sik2, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 





pLKO.1 lentiviral vector for expression 
shRNA targeting mouse Sik3, with 
Puromycin antibiotic resistant gene for 
selection stable cell line.
The RNAi Consortium 




Name Description Source/reference Used in
siNT pool Non-targeting siRNA pool Dharmacon, D-001819-
10
I
siCTNNB1 pool siRNA pool targeting human CTNNB1 Dharmacon, L-003482-
05
I




Name Source/reference Used in
TRI Reagent MRC, TR118 I, III
NucleoSpin RNA Plus Machery-Nagel, 740984 I
RNeasy Plus Mini Kit Qiagen, 74136 I, III
RNAlater™ Stabilization Solution Ambion, AM7020 III
TaqMan™ Reverse Transcription Reagents ThermoFisher Scientific, N8080234 I, III
KAPA SYBR® FAST qPCR Kits (ABI Prism) 
from Roche
Roche, KK4617 I, III
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Other Major Reagents
Name Source/reference Used in
TAM (tamoxifen) Sigma, T5648 I, III
4-OHT ((Z)-4-hydroxytamoxifen) Sigma, H7904 I
DAPT Sigma, D5942 I
AICAR Tocris Bioscience, A611700 I
DCA (Dichloroacetate) Sigma, 347795 I
2-DG (2-deoxy-D-glucose) Sigma, D6134 I
Phloretin Sigma, P7912 I
UK-5099 R&D, 4186 I
Lactate Sigma, L7022 I
Pyruvate Sigma, P2256 I
MG132 Calbiochem, 474791 I
CHIR (CHIR99021) Sigma, SML1046 I
AR (AR-A014418) Sigma, A3230 I
LiCl (Lithium Chloride) Sigma, L9650 I
Curcumin Enzo LifeSci, ALX-350-M010 I
VPA (Valproic acid) Sigma, PHR1061 I
TSA (Trichostatin A) Sigma, T8552 I
BT3 (Butyrolatone 3) Enzo LifeSci, ALX-270-411-M005 I
CCCP (Carbonyl cyanide 3-
chlorophenylhydrazone)
Sigma-Aldrich, C2759 I
Rotenone Sigma-Aldrich, 45656 I
Antimycin A Sigma-Aldrich, A8674 I
A-769662 Abcam, ab120335 I
Alcian Blue Sigma, B8438 I
Target Retrieval Solution, pH 9 DAKO, S236784-2 I, III
Target Retrieval Solution, Citrate pH 
6.1
DAKO, S169984-2 I, II, III
SignalStain DAB Substrate Kit Cell Signaling, #8059 I, II, III
Celecoxib Searle-Pharmacia, Pfizer II
N-methyl-N-nitrosourea Sigma-Aldrich II
Tissue-Tek® O.C.T.™ Compound SAKURA, 4583 III
Ruxolitinib Incyte, INCB18424 III
Mouse IL-11 ELISA Kit Sigma, RAB0251 III
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2. Methods 
The methods are listed below alphabetically, and the details are described in original publications.
Method/Protocol Used and described in
Adenovirus transduction III
Alcian blue staining I
DNA and RNA transfection I, III
ELISA III
Flow cytometry analysis and sorting I, III
Frozen sections III
Generation of mouse embryonic fibroblasts (MEFs) III
Generation of shRNA constructs I, III
Gene Set Enrichment Analysis (GSEA) I, III
Image acquisition and analysis I, II, III
Immunofluorescence analysis and quantification I, III
Immunohistochemistry I, II, III
Intestinal crypt and stem cell isolation I
Intestinal organoid culture I, III
Intraperitoneal (IP) injection I, III
Lentivirus production and transduction I, III
Mammalian cell culture I
Mouse breeding and genotyping I, II, III
Mouse dissection I, II, III
Mouse husbandry and handling I, II, III
Quantitative real-time PCR (qRT-PCR) I, III
RNA sequencing, data acquisition and analysis I, III
Statistics I, II, III
Tissue processing, embedding and sectioning I, II, III
Total RNA extraction I, III




RESULTS AND DISCUSSION 
LKB1 links energy metabolism to ATOH1-mediated ISC fate determination (I) 
RESULTS (I) 
1. Lkb1 loss in LGR5+ ISCs leads to crypt-specific phenotypes 
Experimental mouse models were generated from previously established mouse strains including 
Lgr5EGFP-IRES-creERT2/+ mice (Barker et al. 2007), Lkb1flox (Lkb1fl) mice (Bardeesy et al. 2002), and 
Rosa26LSL-TdTomato mice (Madisen et al. 2010). Eight to twelve week-old Lgr5EGFP-IRES-creERT2/+; 
Lkb1flox/flox; Rosa26LSL-TdTomato/+ mice were intraperitoneally injected with a single dose of 
Tamoxifen in order to both achieve inactivation of Lkb1 alleles in LGR5+ ISCs and allow lineage 
tracing with TdTomato expression (Lkb1Lgr5-KO) (Model explained in Figure 2). The control group 
consisted of Lgr5EGFP-IRES-creERT2/+; Rosa26LSL-TdTomato/+ mice that received the same Tamoxifen 
treatment. A highly efficient recombination rate (close to 100%) in ISCs (Lgr5Hi) was detected by 
flow cytometry analysis of TdTomato expression from those mice five days post Tamoxifen 
induction, and further confirmed with LKB1 protein loss in TdTomato+ crypts by 
immunohistochemistry. At the same time point, however, Paneth cell recombination was not yet 
noted at a significant level. 
 
 
Figure 2. Deletion of Lkb1 in LGR5+ ISCs and lineage tracing to mark Lkb1-deleted (Lkb1 KO) 
ISCs and progeny. In Lgr5EGFP-IRES-creERT2/+; Lkb1flox/flox; Rosa26LSL-TdTomato/+ mice. (Left) Lkb1fl 
alleles are not recombined in the absence of Tamoxifen, therefore, functional Lkb1 is expressed in 
both ISCs and their progeny. ISCs express Lgr5-GFP (in green) and are not labeled with TdTomato. 
(Right) Tamoxifen treatment activates Cre recombinase, which irreversibly induces both 
recombination of the Lkb1fl alleles and activation of the TdTomato reporter. Therefore, Lkb1 deletion 
and TdTomato lineage tracing first happen in ISCs and are inherited by their progeny upon 
differentiation. The recombined ISCs express both GFP and TdTomato (in yellow) and recombined 
progeny only express TdTomato (in red). 
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The GFP and TdTomato expression analyzed from the Lkb1Lgr5-KO small intestine (up to 600 days 
post Tamoxifen induction) and from the organoid formation assay (Sato et al. 2009) from Lkb1Lgr5-
KO crypts demonstrated the long-term maintenance of Lkb1-depleted intestinal stem cells and their 
capacity of producing progeny.
Despite the long term maintenance of some Lkb1-deficient ISCs, we also noted comparable
reductions in both the total GFP+ crypt number (47%, based on immunofluorescence staining 
quantification) and total GFP+ LGR5+ ISC number (49%, based on flow cytometry analysis) after
five days in Lkb1Lgr5-KO mice compared to control. In addition, TdTomato detection was more 
often found to be restricted to the villi in these mice, suggesting that ISCs in some of the Lkb1-
deleted crypts had differentiated. No further decrease of Lkb1Lgr5-KO ISCs was noted at later time 
points (up to 600 days).
Taken together, Lkb1 deletion leads acutely to a reduction in a subset of ISCs in a crypt-specific 
manner, while in other crypts, Lkb1-deficient stem cells are maintained and functional in the long
term.
2. Transcriptomic analysis reveals Atoh1 induction and secretory progenitor signature in 
Lkb1Lgr5-KO ISCs 
A FACS-based LGR5+ ISC purification method established by the Clevers lab (Sato et al. 2009)
and RNA sequencing (RNA-seq) technology provide the opportunity to decipher the molecular 
changes following Lkb1 deletion in ISCs (Lgr5Hi) and progenitors (Lgr5Low). The transcriptomes 
of both Lgr5Hi and Lgr5Low populations five days after Lkb1 loss were compared with control 
samples. To improve the previously established wild-type (WT) ISC signature and progenitor 
signature (Muñoz et al. 2012), we took the union of 733 significantly altered transcripts between 
Hi and Low populations in our study, and 1056 transcripts identified by re-analyzing the  
microarray data from Muñoz et al. (Muñoz et al. 2012) displaying a strong similarity with our 
study. The union generated a robust 464-gene ISC signature (ISC_464) and a 538-gene progenitor 
signature (Progenitor_538). While several of the well-characterized ISC/quiescent/+4 markers,
such as Lgr5, Olfm4, Bmi1, mTert, Hopx, and Lrig1 were not significantly altered in Lkb1Lgr5-KO
ISCs (Lkb1Lgr5-KO_Hi) compared to WT controls, gene set enrichment analysis (GSEA) with the 
ISC_464 and Progenitor_538 signatures suggested a shift of the Lkb1-deleted ISCs toward the 
progenitor lineage.
To further characterize the Lkb1Lgr5-KO_Hi cells, we compared their signature to the signatures of 
secretory progenitors (Sec-Pro) and enterocyte progenitors (Ent-Pro). Remarkably, the Lkb1Lgr5-
KO_Hi cells displayed significant similarity with three different Sec-Pro signatures generated from 
existing datasets (Van Es et al. 2012; Basak et al. 2014; Kim et al. 2014). By contrast, no 
significant similarity was noted between the Lkb1Lgr5-KO_Hi cells and an Ent-Pro signature
obtained from Atoh1-deleted cells (Kim et al. 2014). When comparing the Lkb1Lgr5-KO_Low cells, 
the similarity with the Sec-Pro signatures was even more pronounced, but some similarity was 
also noted with Ent-Pro. These results indicate at the molecular level that Lkb1 loss in ISCs leads 
to a predominance of secretory characteristics.
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Leading edge genes from the comparison of Lkb1Lgr5-KO_Hi cells with Sec-Pro signatures 
contained a number of secretory markers including the master regulator of secretory cell lineage,
Atoh1 (Q. Yang et al. 2001; Shroyer et al. 2007), and its downstream targets, Gfi1 (Shroyer et al. 
2005) and Neurog3 (Jenny et al. 2002). The same analysis also identified Atoh1 and several 
secretory markers in Lkb1Lgr5-KO_Low cells. Although the Atoh1 level in Lkb1Lgr5-KO_Hi cells was 
significantly higher than in WT_Hi cells, the level of induction was lower than noted between
WT_Hi and WT_Low, consistent with the retained stem cell capacity of the Lkb1Lgr5-KO cells (Kim 
et al. 2016). It is also notable that the Lkb1Lgr5-KO_Hi signature is similar to an Atoh1TdTomatoLgr5+
signature (Ishibashi et al. 2018).
The enrichment of secretory genes noted in Lkb1-deleted Hi and Low cells was associated with
an increase of mucin-secreting cells (Alcian blue positive) in Lkb1-deleted crypts and villi marked 
by TdTomato, consistent with increased and perturbed secretory cell differentiation noted 
following Lkb1 loss in differentiated lineages (Shorning et al. 2009).
3. Induction of the secretory phenotype in Lkb1-deficient cells is dependent on Atoh1 
shRNA-mediated depletion of LKB1 in Ls174t cells—which have high LGR5 (Barker et al. 2007),
low ATOH1 (Kazanjian et al. 2010), and functional LKB1—leads to increased expression of 
ATOH1 mRNA and a secretory phenotype that is evidenced by increased mucin production, which 
well-recapitulates the in vivo phenotype. When ATOH1 is depleted in addition to LKB1, the cells 
lack mucin production. These results indicate that LKB1 suppresses the ATOH1-mediated 
secretory phenotype.
4. Lkb1 represses ATOH1 independently of Wnt and Notch signaling 
Atoh1 has been identified to be regulated in ISCs by the niche factors, Wnt (Shi et al. 2010; Tian 
et al. 2015) and Notch (Van Es et al. 2005; Kazanjian et al. 2010). Our GSEA analysis of RNA-
seq data did not demonstrate significant changes in Wnt and Notch signaling (besides Atoh1) in 
Lkb1-deleted ISCs.
The notion that Lkb1 regulates Atoh1 independently of Wnt signaling was also supported by the 
observation that LKB1 represses ATOH1 in Ls174t cells with a constitutively active ß-catenin and 
Wnt pathway (Li et al. 2012). To investigate this directly, we depleted ß-catenin in Ls174t cells,
where ATOH1 expression was decreased in consistence with an earlier report (Shi et al. 2010),
and observed that LKB1 depletion induces ATOH1 both in control and ß-catenin-depleted 
conditions.
LKB1 knockdown in Ls174t cells did not affect Notch activation as measured by cleaved Notch 
1, consistent with the GSEA results from ISCs. To further investigate the interrelationship of Lkb1
and the Notch pathway in Atoh1 induction, we analyzed the ATOH1 and Notch target, HES1,
following LKB1 knockdown or Notch inhibition by 20μM γ–secretase inhibitor DAPT, which 
efficiently blocks Notch activity. Consistent with results from the ISC RNA-seq analysis, LKB1
knockdown did not affect HES1 or its downregulation by DAPT. As expected, Notch inhibition 
induced ATOH1, similar to the LKB1 knockdown. Importantly, the combination of LKB1
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knockdown and Notch inhibition led to significant further induction of ATOH1. The independent 
regulation of Atoh1 by Lkb1 and Notch inhibition was also supported by a further reduction of
ISCs in DAPT-treated Lkb1Lgr5-KO organoids.
Collectively, the cell line studies demonstrated that ß-catenin knockdown did not override the 
effect of Lkb1, and that Notch inhibition showed a synergistic effect with Lkb1 in both the cell 
line and ex vivo organoid models. Together with the RNA-seq analysis, we concluded that Lkb1
represses Atoh1 independently of Wnt and Notch signaling.
5. AMPK is not required for ATOH1 repression by LKB1 
Urged by recent studies indicating the critical role of cellular metabolism in regulating ISC 
functions (Rodríguez-Colman et al. 2017; Schell et al. 2017; Mattila et al. 2018), we became 
interested in asking whether metabolism contributes to ATOH1 repression by LKB1, thereby
influencing the secretory differentiation. One of the important downstream substrates of LKB1 is 
AMPK, which functions as an energy sensor that regulates multiple metabolic pathways (Hardie 
and Alessi 2013). Therefore, we investigated whether the ATOH1 induction following LKB1 loss 
is mediated by AMPK. 
The allosteric activator, A769662, can activate AMPK in the absence of LKB1 (Göransson et al. 
2007), thus providing the possibility to restore AMPK activation in LKB1-depleted cells. LKB1
deletion indeed eliminated AMPK activity in Ls174T cells, as measured by the level of ACC 
phosphorylation, and this could be restored by A769662 treatment without affecting ATOH1
induction. In addition, we also found that neither AMPKalpha1 (PRKAA1) nor alpha2 (PRKAA2)
depletion was sufficient to induce ATOH1 expression. These results suggest that AMPK is not 
required for ATOH1 repression by LKB1.
6. The PDK inhibitor, DCA, attenuates ATOH1 induction and alleviates impaired respiration 
in LKB1-deficient cells 
To look for new ways in which ATOH1 might be regulated by LKB1, we screened the following 
compounds in Ls174t cells by adding them respectively to the cells in culture to see which 
compound would modulate the ATOH1 induction upon LKB1 depletion. The compounds include 
those that modulate glycolysis and oxidative phosphorylation (Rodríguez-Colman et al. 2017; 
Schell et al. 2017), and also those that regulate ATOH1 by targeting i) proteasome degradation
(Peignon et al. 2011); ii) GSK3ß (Peignon et al. 2011; Yin et al. 2014); iii) histone acetyl-
transferases (Stojanova, Kwan, and Segil 2015); or iv) histone deacetylases (Yin et al. 2014; 
Stojanova, Kwan, and Segil 2015). Interestingly, the only compound identified to modulate 
ATOH1 induction following LKB1 depletion was the pyruvate dehydrogenase kinase (PDK) 
inhibitor, dichloroacetate (DCA).
PDK inhibits pyruvate dehydrogenase (PDH) and thereby oxidative phosphorylation (OXPHOS) 
and thus cellular respiration. Thus, DCA works to inhibit aerobic glycolysis and promote 
OXPHOS. We measured the oxygen consumption rate (OCR) following DCA treatment, and 
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found that DCA can partially restore the impaired basal and maximal respiration in LKB1-
deficient cells.
We went back to our RNA-seq data , an unbiased analysis of pathways deregulated in Lkb1-
deleted ISCs and progenitors revealed a significant enrichment in an OXPHOS signature.
Interestingly, the top-ranked gene in Lkb1Lgr5-KO ISCs was Pdk4 in this analysis, whereas several 
other OXPHOS genes were more significantly altered later in the Lkb1Lgr5-KO progenitors. Pdk4
was the only PDK (the PDK family includes PDK1, PDK2, PDK3, and PDK4) induced by Lkb1
deletion in ISCs and this was recapitulated in Ls174t cells. Importantly, PDK4 depletion 
attenuated the induction of ATOH1 in LKB1-depleted Ls174t cells, indicating a critical role of 
PDK4 in mediating the repression of ATOH1 by LKB1.
Taken together, these results demonstrated that LKB1 specifically represses PDK4, and thereby 
maintains normal OXPHOS. It also provided evidence that the repression of ATOH1 by LKB1 is 
mediated by suppressing PDK4.
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DISCUSSION (I) 
Our findings reveal the important role of Lkb1 in ISC homeostasis. The specific deletion of Lkb1
in LGR5+ cells generates ISCs with elevated Atoh1, yet without a noticeable effect on stem cell 
functions in some of the targeted crypts. The ISCs with a high level of Atoh1 share molecular 
similarities with DLL1+ secretory progenitors (Van Es et al. 2012) and recently described 
ATOH1+ secretory lineage intestinal epithelial cells (Ishibashi et al. 2018). Those secretory 
progenitors can revert to ISCs following tissue damage, therefore it would be interesting to 
investigate whether this is associated with LKB1 activation.
However, in other crypts Lkb1 deletion leads to a rapid loss of ISCs prior to any noticeable 
targeting of the niche Paneth cells indicating that Lkb1 loss disrupts homeostasis in these ISCs in 
a cell-intrinsic manner. The two ISC fates following Lkb1 loss suggest crypt-specific differences 
in ISCs as identified by Snippert et al. (Snippert et al. 2010). It is tempting to speculate that the 
observed heterogeneity of ISC Atoh1 levels (Kim et al. 2016) would underlie the two fates noted 
in Lkb1 deficient ISCs, considering the critical role that Atoh1 levels play in ISC secretory 
differentiation. In this case, Atoh1 levels would be regulated in a crypt-specific manner.
The altered ISC homeostasis was not noted in Lkb1Lgr5-Het mice (data not shown), suggesting that
the phenotype is not penetrant in PJS models, where Lkb1 acts as a haploinsufficient tumor 
suppressor (Rossi et al. 2002), and where tumorigenesis is driven by stromal cells (Katajisto et al. 
2008; Ollila et al. 2018). However, loss-of-heterozygosity (LOH) analysis identified regions with 
complete loss of LKB1 in some PJS patient polyps (Hemminki et al. 1997), a phenomenon that 
has not been noted in the mouse models. Consistent with our results, these regions display a 
secretory lineage enrichment based on a high proportion of goblet-like cells, and have been 
suggested to represent progression of PJS tumors (Hemminki et al. 1997). Our Lgr5-Lkb1-KO
model provides an opportunity to explore this further.
Atoh1 has been coined the gatekeeper of secretory differentiation based on its induction in ISCs 
through regulation by Notch (van Es et al. 2010; Kim and Shivdasani 2011) and Wnt (Tian et al. 
2015) signaling. An earlier pan epithelium deletion of Lkb1 (Shorning et al. 2009) noted an 
enrichment of secretory cell lineages, which was correlated with increased Notch signaling 
without specification of the cell type(s) involved. The ISC-specific Lkb1 deletion used here 
enabled the distinction of cell-intrinsic signaling changes in ISCs and identified Atoh1 induction 
as an early change that is independent of Notch signaling.
Our findings demonstrated that the loss of the metabolic sensor, Lkb1, in ISCs leads to 
dysregulated expression of OXPHOS-associated genes, including a marked induction of Pdk4, an 
observation that is consistent with increasing evidence that cellular metabolism has a major impact 
on adult stem cell (including ISCs) function (Rodríguez-Colman et al. 2017). Further evidence 
from our in vitro data indicates compromised OXPHOS in LKB1-depleted cells, which can be 




Figure 3. Lkb1 maintains LGR5+ ISC homeostasis by repressing Atoh1-mediated secretory cell 
differentiation, via Pdk4-regulated energy metabolism. (Left) In presence, Lkb1 contributes to the 
repression of Atoh1 to maintain ISCs homeostasis by restricting Atoh1-mediated secretory cell 
differentiation and maintains normal cell respiration. (Right) Lkb1 loss induces Atoh1 in ISCs, a 
process which is mediated by elevated Pdk4 and reduced OXPHOS, and this leads to the acquisition 
of a Sec-Pro signature while still maintaining the stem cell identity and functions, and thereby an 
increase in the differentiation specifically towards secretory cell lineages. 
 
respiratory capacity of mitochondria also gets compromised following LKB1 loss, suggests that 
there are also other alterations in mitochondria in addition to their functional regulation, and 
provides a possible explanation as to why the basal respiration in LKB1-deficient cells cannot be 
completely rescued by PDK inhibition. Taking into account the previous observation that the 
induction of ATOH1 following LKB1 depletion is dependent on PDK4 raises the possibility that 
Lkb1 represses Pdk4 in order to restrict Atoh1-mediated secretory cell differentiation in ISCs 
(model explained in Figure 3). In several other systems where Lkb1 is required for stem cell 
survival and function, including regulatory T cells (K. Yang et al. 2017; Wu et al. 2017; He et al. 
2017) and HSCs (Gurumurthy et al. 2010; Nakada, Saunders, and Morrison 2010; Gan et al. 2010), 
impaired OXPHOS following Lkb1 loss has been also noted. Thus, our findings suggest that 
LKB1-regulated energy metabolism also plays an important role in stem cell fate determination 
in addition to its crucial impact on cell survival. 
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MNU treatment provokes Lkb1+/- polyposis independently of COX-2 (II) 
RESULTS (II) 
1. MNU treatment promotes Lkb1+/- polyposis 
MNU treatment led to a decrease in survival of Lkb1+/- mice compared to wildtype mice with the 
same treatment. The gastric polyp burden was dramatically increased compared to untreated 
Lkb1+/- mice. This increase was due to both an increase in polyp size, through enhanced epithelial
proliferation, and an increase in polyp number, including the number of small polyps. These
results suggest that MNU treatment promotes both the initiation and development of PJS polyposis.
2. Histological analysis in MNU-treated mice revealed no malignant transformation 
Histological analysis of gastric mucosa revealed no change in polyp morphology under the MNU 
treatment, except only one case of dysplasia, among all the 18 Lkb1+/- and 41 wildtype mice that 
include in total 104 gastric Lkb1+/- polyps and 11 wildtype gastric lesions.
p53 is induced in response to DNA damage (Kastan et al. 1991). Mutated p53 was found in 5 of 
15 analyzed gastric Lkb1+/- polyps upon MNU treatment by mutant conformation-specific 
PAb240 antibody. However, there was no correlation between the inactivated p53 and the detected 
dysplasia case.
3. MNU treatment does not affect gastric gland differentiation in Lkb1+/- mucosa 
Previous work in our lab demonstrated that stomach glands display aberrant or incomplete
differentiation in Lkb1+/- mouse, as detected by pepsinogen C staining showing increased 
frequency of PAPG (Udd et al. 2010). However, in Lkb1+/- mice there was no further increase of 
PAPG above the basal level upon MNU treatment, though wildtype mice showed a pattern of 
increased PAPG with MNU treatment. These results suggest that the mechanism underlying 
PAPG in Lkb1+/- mice is different than carcinogen-induced PAPG in wildtype mice, and could 
rather be a sign of nascent polyposis.
4. COX-2 inhibition does not suppress MNU-induced Lkb1+/- polyposis acceleration 
In Lkb1+/- mice, the COX-2 inhibitor, celecoxib, suppresses polyposis (Udd et al. 2004). Celecoxib 
administration slightly but not significantly decreased both the mortality and the gastric polyp 
burden in Lkb1+/- mice that had received MNU treatment. The results demonstrated that COX-2




Treatment with the mutagenic carcinogen MNU could generate additional mutations, therefore 
provide us an opportunity to evaluate the effect of mutagenesis on Peutz-Jeghers polyposis in 
Lkb1+/- mice. We observed that MNU treatment accelerated polyposis by increasing both the size 
and number of polyps in Lkb1+/- mice, suggesting that additional mutations may promote both the 
initiation and subsequent growth of Lkb1+/- polyps. However, MNU treatment showed no effect 
on defective gastric gland differentiation (assessed by PAPG), which has been considered as an 
early sign of polyp initiation (Udd et al. 2010). Thus, it would be interesting to look for the reason 
behind increased polyp initiation in a future study.
Another observation was that MNU treatment accelerated Lkb1+/- polyposis without causing 
malignant transformation in the polyps. This result indicates that mutations leading to malignant 
transformation are not favored in the Lkb1+/- stomach, consistent with a previous report that Lkb1 
loss drives benign hyperproliferation that is resistant to malignant transformation (Bardeesy et al. 
2002).
The notion we had from our previous study is that COX-2 promotes the growth of polyps rather 
than their initiation (Udd et al. 2004). In this study, when the Lkb1+/- polyp initiation had been 
provoked by mutagenesis that also affected other genes, COX-2 inhibition with celecoxib had no 
particular effect on limiting Lkb1+/- polyp growth. The result suggests that celecoxib alone is not
efficient in suppressing PJS polyposis when the polyposis has been accelerated by additional 
mutations. This would probably also explain why celecoxib represses gastric polyposis only in a 
subset of PJS patients (Udd et al. 2004).
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Stromal Lkb1 deficiency leads to gastrointestinal tumorigenesis involving an 
induced inflammatory program (III) 
RESULTS (III) 
Two alternative strategies were used to achieve stromal Lkb1 deletion: the Twist2-Cre (also known 
as Dermo1-Cre) allele targeting mesenchymal progenitor cells, and the fibroblast-specific protein-
Cre (Fsp1-Cre, also known as S100A-Cre) allele targeting fibroblasts.
We first studied the heterozygous Lkb1 deletion in stroma by crossing Twist2-Cre and Fsp1-Cre
mice with Lkb1flox mice to generate Twist2-Cre;Lkb1fl/+ (Lkb1TwKO/+) and Fsp1-Cre;Lkb1fl/+
(Lkb1FspKO/+) mice. Lkb1TwKO/+ mice showed full penetrance in polyp formation, in addition to
comparable survival and tumor burden to previously reported Lkb1+/- mice (Rossi et al. 2002).
Lineage tracing (Rosa26R-mTmG) analysis confirmed exclusive stromal recombination in 
Lkb1TwKO/+ mice. These results demonstrated that heterozygous Lkb1 loss in stroma is sufficient 
to drive PJS polyposis. Lkb1FspKO/+ mice showed lower tumorigenic potential with very limited 
polyp formation (both the penetration and tumor burden), and this is probably due to low 
recombination frequency.
We next studied homozygous Lkb1 deletion in stroma by generating Fsp1-Cre;Lkb1fl/fl
(Lkb1FspKO/FspKO) mice (the Twist2-Cre;Lkb1fl/fl is embryonic lethal). The Lkb1FspKO/FspKO mice
rapidly developed polyps with full penetrance already at four months of age, and the polyps 
displayed dramatically expanded Lkb1-deficient stroma, as detected by the reporter (Rosa26R-
LacZ). Further study with the Lkb1FspKO/FspKO;Rosa26R-Confetti tumors demonstrated an
oligoclonal origin of the tumor stroma. By contrast, the analysis in polyps of Lkb1+/– mice carrying 
the Lgr5-EGFP-IRES-ERT2 allele with Rosa26LSL-TdTomato/+reporter demonstrated that the 
epithelial compartment in polyps did not display clonal growth. Together with the evidence from 
histological analysis showing stromal cells with characteristics of activated and contractile 
myofibroblasts, and epithelial cells with increased proliferation, these results indicate that PJS
polyps form from clonally expanding stromal myofibroblasts and reactively hyperproliferating 
epithelia.
Transcriptome analysis (RNA-seq) from Lkb1FspKO/FspKO polyps revealed prominent inflammatory 
hallmarks, as also seen from the analysis of human PJS polyp transcriptomes. One of the top hits
was JAK/STAT signaling in both cases, consistent with the observation from the polyps showing 
activated JAK/STAT3 signaling detected by Western blotting. Notably, histological staining 
revealed that the JAK/STAT3 pathway was activated in the epithelial compartment of the polyp.
Next, we identified IL-11 secreted from fibroblasts as the potential activator of JAK/STAT3
signaling in polyps. Finally we found that pharmacological inhibition of JAKs with the JAK1/2 
inhibitor, Ruxolitinib (Quintás-Cardama et al. 2010) (which is already clinically approved for 
myeloproliferative diseases), can reduce the PJS polyp development in mice.
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DISCUSSION (III) 
Our work demonstrated that mesenchymal-progenitor or stromal-fibroblast–specific deletion of 
Lkb1 is sufficient for PJS polyposis. Taking into account the previous observations that Lkb1 loss 
from smooth muscle cells leads to the development of PJS-type polyps (Katajisto et al. 2008), and 
that epithelial deletion failed to induce polyp formation (Shorning et al. 2009, 2012), we conclude 
that PJS polyposis is a stromal disease. Interestingly, the observations in both this study and a 
previous study (Katajisto et al. 2008) indicate that homozygous deletion of Lkb1 in stroma 
enhances tumorigenicity while heterozygous deletion is sufficient for polyposis. Thus, it is 
tempting to focus future LOH studies in PJS on the stromal compartment of tumor.
Mechanistically, Lkb1 loss in gastric stromal cells leads to clonal expansion of stromal cells and 
activation of an inflammatory program involving the IL-11–JAK/STAT3 pathway, which 
promotes the expansion of stroma and overgrowth of epithelia. Together with the study of Lkb1
in T cells by Poffenberger et al. (Poffenberger et al. 2018), a critical role of inflammatory signals 
in tumorigeneses has been revealed, that they can profoundly alter the microenvironment and fuel 
tumor formation. In addition, the findings from both our work and Poffenberger et al. also suggest 
that JAK inhibitors may be potential new therapeutic modalities for GI and other tumors arising 
in PJS patients for which there are few treatment options.
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CONCLUSIONS 
To conclude the work described in this thesis:
Study I revealed an essential role of LKB1 in the maintenance of intestinal stem cell homeostasis. 
Lkb1 loss induces the master transcription factor Atoh1 and its associated secretory progenitor 
signature in LGR5+ ISCs, therefore perturbs the LGR5+ ISC homeostasis by shifting towards the 
secretory differentiation. The induction of Atoh1 is mediated by increased PDK4 and suppressed 
OXPHOS, independent of well-established Wnt or Notch signaling, and does not require AMPK.
The results identify a novel mechanism in ISCs for cell fate determination involving metabolic 
regulation; establish a critical role of Lkb1-regulatd energy metabolism in stem cell fate 
determination; identify a novel mechanism repressing Atoh1, the master transcription factor of 
secretory fate determination in the ISC, involving suppression of PDK4 and OXPHOS by LKB1. 
These findings are of general interest in terms of the novelty of the identified biology of the 
intestine homeostasis, and provide a connection between metabolism and the fate determination 
of ISCs.
In Study II, we treated Lkb1+/- mice with carcinogen MNU to induce additional mutations, and 
this is to mimic progression in PJS tumorigenesis. We observed that MNU treatment can promote 
Lkb1+/- polyposis demonstrated by reduced survival and increased tumor burden, but was not 
accompanied by consistent substantial histological changes in those polyps, supporting the notion 
that LKB1 loss drives benign growth but resistant to malignant transformation (Bardeesy et al. 
2002). Focal area of mutated p53 was detected in MNU-treated Lkb1+/- polyps, but unlinked to 
malignant progression in this setting. COX-2 inhibition with celecoxib is not sufficient to prevent 
the Lkb1+/- polyposis accelerated by MNU treatment. Study III used various stromal-Lkb1-deletion 
mouse models to decipher the originating cell type and molecular mechanism underlying the 
Lkb1+/- polyposis. Loss of Lkb1 in stroma leads to clonal expansion of stromal cells and full 
penetrance of gastric polyp formation, strongly supporting a stromal-deriving of PJS polyps. The 
activation of an inflammatory program involving the JAK/STAT signaling was noted as a major 
alteration in PJS and mouse model polyps in this study. In addition, treatment with the JAK1/2 
inhibitor ruxolitinib dramatically decreased polyposis in Lkb1-dificent mice. Therefore, this study
demonstrates that PJS polyposis is a stromal-deriving disease mediated by induced inflammatory 
program that involves the IL-11–JAK/STAT3 pathway. Collectively, the findings in II and III 
help us to further understanding PJS, and provide potential therapeutic opportunities. 
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